Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Active not recruiting 11Completed 8Recruiting 6Terminated 4Withdrawn 3Suspended 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Burkitt Lymphoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Multi-centric Castleman's Disease 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphoid 1Hodgkin Disease 1Hematologic Neoplasms 1Breast Neoplasms 1Blast Crisis 1

Interventions

Rituximab 67Cyclophosphamide 41fludarabine phosphate 17Etoposide 17Doxorubicin 17Vincristine 16Prednisone 16Filgrastim 14Mycophenolic Acid 13Cyclosporine 13Lenalidomide 12Antilymphocyte Serum 12Gemcitabine 11Radiotherapy 10fludarabine 9Peripheral Blood Stem Cell Transplantation 9Methotrexate 9Whole-Body Irradiation 8Tacrolimus 8Melphalan 8Carboplatin 8Bortezomib 8venetoclax 7Dexamethasone 7Cord Blood Stem Cell Transplantation 7Busulfan 7ibritumomab tiuxetan 6Ifosfamide 6Flow Cytometry 6obinutuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Large B-Cell, Diffuse × CT-P10 × Clear all
NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

University of Washington

Phase 2 Terminated
18 enrolled 14 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03864419 2024-01-03

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Fred Hutchinson Cancer Center

Phase 1 Terminated
18 enrolled
Lymphoid

Multi-centric Castleman's Disease, Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04156828 2023-06-29

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

University of Washington

Phase 1 Terminated
12 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT01434472 2021-07-20

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Terminated
20 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡